Relieve allergy symptoms

This comes from the same forty drivers and the same four sessions, so it inherits that setting: a simulator, a daytime dose, driving one hour later. A failure of self-rating to predict performance across one hour-long test is not proof that people can never judge their own impairment.

For the other oral decongestants pooled in that search, a week or more of daily use changed systolic pressure by 0.91 mmHg on average, at very low certainty. None of those trials used phenylephrine, so the figure cannot be carried over to it.

The trial's own title calls it open-label, so people may have known what they were taking. That usually inflates a self-rated benefit rather than hiding one. Everyone in it had hay fever, not a cold.

All four trials were in hay fever, so none tested a blocked nose from a cold. Two of them gave a single dose and followed congestion for 6 hours. The largest used a 30 mg slow-release tablet, not the 10 mg tablet sold in cold remedies.

The source is a clinical reference chapter summarising other work rather than a study. It names these effects without giving a rate for any of them, so this says what the drug does at ordinary doses, not how likely each is in a given person.

A panel of experts weighs evidence and then votes, so strong records a committee's confidence rather than an effect size. The list carries its own exception: treating a severe allergic reaction may still be appropriate. The harms bundled into one line run from dry mouth to contested dementia evidence.

The instruction sits on the allergy liquid. The dedicated sleep aids handle the question differently, by excluding anyone under 12 outright, so the sentence belongs to this label, not to diphenhydramine labelling in general. A label requirement is not evidence about how often harm follows.

Twenty-one people, about seven per group, with standard deviations of 4.2, 2.5 and 1.8 hours around those means. The dose was 1.25 mg per kilogram, roughly 86 mg in the adults, well above the 25 to 50 mg a tablet gives. A separate trial at 25 mg found no age difference at all, most likely because of that gap.

A label count is not a product count and not a measure of how many people take these. The same physical product carries several records across repackagers and store brands, so duplicates sit inside that figure. Counts drift as labels are added and withdrawn, which is why the date belongs with the number.

The 300 mg figure comes from a clinical reference chapter for the allergy indication, not from an over-the-counter label, so quoting it about sleep would misdescribe what those products allow. The 50 mg figure is read off one US sleep-aid label, and other markets word their limits differently.

More phenylephrine in the blood is not shown to mean a clearer nose: no study tested whether the pairing relieves congestion better. The studies gave single doses to healthy volunteers. Their authors work for a company that makes combination painkillers.

The review's young-children finding covers cold remedies with mixed ingredients, most of them other decongestants, so it is not phenylephrine's own result. The children absorbed the drug much as adults do, with somewhat lower peak levels.

A label lists what the maker is permitted to claim under US rules, not proof that the claim holds. Labels change, and this one took effect in June 2026.

An advisory vote is advice to the FDA, not a ruling; the agency decides separately. Members noted that no data measure the drug in the nasal lining.

The status is dated: it reflects the FDA's order page on 26 September 2026. The proposal concerns effectiveness, not safety. It covers phenylephrine taken by mouth, not nasal sprays.

No study has measured phenylephrine in the lining of the nose, where it would have to act. So the link between little drug in the blood and no relief is inferred, not shown.

These are reports of individual cases gathered in a narrative review, so they show that it can happen, not how often.

Both studies gave single doses, so neither shows what a day or a week of doses does. Everyone in them had normal blood pressure. The larger study was run by employees of a phenylephrine maker. A model built from eye-drop data predicts a larger rise when 10 mg is taken with 1,000 mg of acetaminophen, 12.3 against 4.2 mmHg in average arterial pressure, a prediction nobody has measured.

Each person took all three in turn, and the authors flag that earlier doses may have carried over: in the first round alone, phenylephrine's gap over placebo was 64% of pseudoephedrine's, against 17% across all rounds. It tested a single dose. The congestion came from pollen, not a cold.

The dose was daytime, with driving an hour later, the reverse of the bedtime-then-morning pattern a sleep aid creates. On reaction time to a car blocking the lane, alcohol was slowest, so worse than alcohol holds for the measures the paper led with, not every one. The comparator's maker funded the trial.

Fifty milligrams of diphenhydramine impaired driving more than alcohol at roughly the legal limit, and 25 mg looked like placebo. Both are sold as normal doses, so what separates them is a step between two amounts, not a dispute about one.

The English null is wide: a real 20 to 30% increase sits inside its range. The Taiwanese comparison group is small, 36,081 non-users against 677,971 users, and people with hay fever who take nothing are unlikely to resemble those who do. Neither design separates the drug from the reason it was taken.

Whether antihistamines raise dementia risk is unsettled. English prescription records show no significant link, Taiwanese dispensing records a rise with dose, and English records miss most shop-bought use, so neither can correct the other.

The conditions these drugs treat, insomnia and low mood among them, are early signs of dementia themselves, so the drug may be marking the illness rather than causing it. Dropping the last twelve months of use blunts that without removing it. One health system in Seattle, shop-bought use only partly captured.

No p-value is given for diphenhydramine against placebo on braking, so the 29 millisecond gap between them cannot be called significant. Both significant braking comparisons involve the sponsor's own drug. Lane wander is a validated road-test measure and still a proxy for crash risk, not crash risk itself.

The road test adds what a simulator cannot: 50 mg of diphenhydramine made drivers weave on a public road. It tested only 50 mg, so it cannot say whether 25 mg, which matched placebo in another trial, impairs driving.

A pattern shared by drugs that do and do not reach the brain points somewhere other than the drug. More medicine dispensed means more medical contact and more chances for a diagnosis to be recorded, and heavier users are sicker to begin with. The authors call for trials to confirm any association.

Case reports cannot show that the decongestant caused the colitis. Unusual cases are the ones that get written up and published. With 3 phenylephrine cases, no rate can be worked out.